Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.34 |
| ▸ | MGMT | P16455 | 2/20 | 0.34 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.34 |
| ▸ | CDK2 | P24941 | 2/20 | 0.34 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23037223 | 0.84 | ALDH1A1 (0.40) | NUDT1POLBCDK1CCNB1MGMT | |
| SCHEMBL23037276 | 0.81 | CDK1 (0.46) | NUDT1POLBCDK1CCNB1MGMT | |
| SCHEMBL23037259 | 0.79 | NUDT1 (0.33) | NUDT1POLBCDK1CCNB1MGMT | |
| SCHEMBL3854995 | 0.78 | NUDT1 (0.33) | NUDT1POLBCDK1CCNB1MGMT | |
| SCHEMBL3853468 | 0.77 | FGFR1 (0.30) | — | |
| SCHEMBL23037242 | 0.76 | NUDT1 (0.44) | NUDT1CDK1CDK2 | |
| SCHEMBL6398516 | 0.75 | THRB (0.44) | NUDT1POLBNPC1ALDH1A1MAPK1 | |
| SCHEMBL3854998 | 0.75 | CDK1 (0.33) | NUDT1POLBCDK1CCNB1MGMT | |
| SCHEMBL23113063 | 0.73 | CDK1 (0.35) | CDK1CCNB1MGMTCCNA2CDK2 | |
| SCHEMBL6004165 | 0.72 | NUDT1 (0.33) | NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603380-B2 | Antiviral acyclonucleoside analogues for use in treating a viral infection | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2023-03-14 | — | — | US | disclosed |
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | NEOVIRTECH (FR) | 2021-03-18 | — | — | US | disclosed |
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | NEOVIRTECH (FR) | 2021-03-18 | — | — | US | disclosed |
| EP-3784680-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | Centre national de la recherche scientifique (FR) | 2021-03-03 | — | — | EP | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-7579332-B2 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2006-11-09 | — | — | US | disclosed |
| EP-1656387-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | GILEAD SCIENCES, INC. | 2005-03-17 | — | — | US | disclosed |
| WO-2005012324-A2 | NUCLEOBASE PHOSPHONATE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11603380-B2 | Antiviral acyclonucleoside analogues for use in treating a viral infection | TYMP, EIF2AK2, ENTPD5 | NUDT1 22/4885POLB 118/4885CDK1 621/4885 |
| US-20210079031-A1 | NEW ANTIVIRAL ACYCLONUCLEOSIDE ANALOGUES | TYMP, EIF2AK2, PNP | NUDT1 27/4885POLB 47/4885CDK1 256/4885 |
| US-20060252729-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | NUDT1 3/4885POLB 94/4885CDK1 359/4885 |
| US-20050059637-A1 | Nucleobase phosphonate analogs for antiviral treatment | TYMP, TK1, NUDT1 | NUDT1 3/4885POLB 94/4885CDK1 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.